SCHEMBL22868047

SCHEMBL22868047

Cc1ccc2c(c1)CCCC2NC(=O)C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
TAS1R3 Q7RTX0 5/20 0.47
TAS1R1 Q7RTX1 5/20 0.47
TAS1R2 Q8TE23 4/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 1/20 0.47
BDKRB1 P46663 1/20 0.45
ALDH1A1 P00352 2/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
USP2 O75604 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
PDE2A O00408 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29741228 0.84 KMT2A (0.50) LMNATAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL3535131 0.82 HTR1A (0.47) LMNATAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL3535129 0.82 HTR1A (0.47) LMNATAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL5951106 0.81 BDKRB1 (0.42) LMNATAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL5951102 0.81 BDKRB1 (0.42) LMNATAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL15006999 0.81 HTT (0.63) LMNATAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL606392 0.81 HTT (0.63) LMNATAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL1266129 0.81 HTT (0.63) LMNATAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL14376711 0.80 CA12 (0.61) LMNATAS1R3TAS1R1TAS1R2BDKRB1
SCHEMBL26779700 0.80 LMNA (0.54) LMNATAS1R3TAS1R1TAS1R2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3994125-B1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMA (US) 2025-12-24 EP disclosed
US-20240299402-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-09-12 US disclosed
US-11957687-B2 Modulators of HSD17B13 and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2024-04-16 US disclosed
US-20230094341-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2023-03-30 US disclosed
EP-3994125-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF Regeneron Pharmaceuticals, Inc. (US) 2022-05-11 EP disclosed
WO-2021003295-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2021-01-07 WO disclosed
WO-2021003295-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2021-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299402-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF HSD17B3, HSD17B11, HSD17B1 LMNA 2981/4885TAS1R3 4634/4885TAS1R1 4793/4885
US-20230094341-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF HSD17B3, HSD17B11, HSD17B1 LMNA 2981/4885TAS1R3 4634/4885TAS1R1 4793/4885
US-11957687-B2 Modulators of HSD17B13 and methods of use thereof HSD17B3, HSD17B11, HSD17B1 LMNA 2981/4885TAS1R3 4634/4885TAS1R1 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.